Machine Learning for Diastology and Heart Failure With Preserved Ejection Fraction: Hype or Hope?

Carolyn S.P. Lam; Jennifer E. Ho

doi:10.1016/j.echo.2022.10.003

Machine Learning for Diastology and Heart Failure With Preserved Ejection Fraction: Hype or Hope?

Carolyn S.P. Lam, Jennifer E. Ho^*

^*Corresponding author for this work

Cardiovascular Centre (CVC)

Research output: Contribution to journal › Editorial › Academic › peer-review

1 Citation (Scopus)

98 Downloads (Pure)

Original language	English
Pages (from-to)	1256-1258
Number of pages	3
Journal	Journal of the american society of echocardiography
Volume	35
Issue number	12
DOIs	https://doi.org/10.1016/j.echo.2022.10.003
Publication status	Published - Dec-2022

Access to Document

10.1016/j.echo.2022.10.003

Machine Learning for Diastology and Heart Failure With Preserved Ejection FractionFinal publisher's version, 440 KBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{bc6b37c4834640e48ac9d868486492af,

title = "Machine Learning for Diastology and Heart Failure With Preserved Ejection Fraction: Hype or Hope?",

author = "Lam, {Carolyn S.P.} and Ho, {Jennifer E.}",

note = "Funding Information: Disclosure Statement: Dr. Lam has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc., Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as cofounder and nonexecutive director of Us2.ai. Dr. Ho has received past research funding from Bayer, AG. Funding Information: Funding Statement: Dr. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore . Dr. Ho is supported by National Institutes of Health grants R01 HL134893 , R01 HL140224 , R0 1HL160003 , and K24 HL153669 . ",

year = "2022",

month = dec,

doi = "10.1016/j.echo.2022.10.003",

language = "English",

volume = "35",

pages = "1256--1258",

journal = "Journal of the american society of echocardiography",

issn = "0894-7317",

number = "12",

}

TY - JOUR

T1 - Machine Learning for Diastology and Heart Failure With Preserved Ejection Fraction

T2 - Hype or Hope?

AU - Lam, Carolyn S.P.

AU - Ho, Jennifer E.

N1 - Funding Information: Disclosure Statement: Dr. Lam has received research support from Bayer and Roche Diagnostics; has served as consultant or on the Advisory Board/Steering Committee/Executive Committee for Actelion, Alleviant Medical, Allysta Pharma, Amgen, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Darma Inc., EchoNous Inc., Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Radcliffe Group Ltd., ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as cofounder and nonexecutive director of Us2.ai. Dr. Ho has received past research funding from Bayer, AG. Funding Information: Funding Statement: Dr. Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore . Dr. Ho is supported by National Institutes of Health grants R01 HL134893 , R01 HL140224 , R0 1HL160003 , and K24 HL153669 .

PY - 2022/12

Y1 - 2022/12

U2 - 10.1016/j.echo.2022.10.003

DO - 10.1016/j.echo.2022.10.003

M3 - Editorial

AN - SCOPUS:85140970752

SN - 0894-7317

VL - 35

SP - 1256

EP - 1258

JO - Journal of the american society of echocardiography

JF - Journal of the american society of echocardiography

IS - 12

ER -